{"entity":{"id":"nct04165590","kind":"trial","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of an investigational treatment in advanced solid tumours, run by CAS Lamvac Biotech Co., Ltd., now recruiting.","summary":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT04165590 by CAS Lamvac Biotech Co., Ltd., with 60 participants planned, started 2019-10-24 and due to reach its primary completion in 2024-04-30.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04165590","url":"https://clinicaltrials.gov/study/NCT04165590"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04165590","phase":"1/2","setting":"Clinical Study of Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","sponsor":"CAS Lamvac Biotech Co., Ltd.","enrolled":60,"outcomes":[]},"route":"/trials/nct04165590/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}